COR CENCORA INC Investor Conferences 8-K Filing 2024 - Performance Update Cencora, Inc. executives will present updates on performance expectations, with adjusted diluted EPS for fiscal year 2024 now expected to be between $13.60 and $13.70, and they have extended a pharmaceutical supply agreement with Evernorth Health Services through September 2029.Get access to all SEC 8-K filings of the CENCORA INC